| Autor: | Diaz-Dinamarca, Diego A., Manzo, Ricardo A., Soto, Daniel A., Avendaño-Valenzuela, María José, Bastias, Diego N., Soto, Paulina I., Escobar, Daniel F., Vasquez-Saez, Valeria, Carrión, Flavio, Pizarro-Ortega, Magdalena S., Wilson, Christian A. M., Berrios, Julio, Kalergis, Alexis M., Vasquez, Abel E. |
| Revista: | Vaccines |
| Año: | 2020 |
| Número: | 1 |
| Paginas: | |
| Volumen: | 8 |
| Abstract: | Vaccine-induced protection against pathogens, especially subunit-based vaccines, are related to antigen properties but mainly in their ability to stimulate the immune system by the use of an adjuvant. Modern vaccines are formulated with a high level of antigen purity, where an efficient adjuvant is necessary. In this context, the use of protein Toll-Like Receptor (TLR) agonists as vaccine adjuvants has been highlighted because of their optimal immunogenicity and minimal toxicity. The Surface Immunogenic Protein (SIP) from Group B Streptococcus (GBS) has gained importance as a new potential protein-based vaccine. Recently, we reported that recombinant SIP (rSIP) expressed by E. coli and purified by High Performance Liquid Chromatography (HPLC) alone induces a protective humoral immune response. In this study, we present the immunomodulatory properties of rSIP as a protein-based adjuvant, as an agonist of TLR. To this end, we showed that C57BL/6 bone marrow-derived dendritic cells pulsed by rSIP resulted in enhanced CD40, CD80, CD86, and Major Histocompatibility Complex (MHC) class II as well as increased secretion proinflammatory cytokines Interleukin (IL)-6, Interferon (IFN)-?, Tumor Necrosis Factor (TNF)-?, and IL-10. Next, we investigated the in vivo effect of rSIP in the absence or presence of ovalbumin (OVA) on antigen-specific antibody secretion in C57BL/6 mice. Immunization with rSIP plus OVA showed that anti-OVA IgG2a and IgG1a increased significantly compared with OVA alone in C57BL/6 mice. Also, the immunization of rSIP plus OVA generates increased serum cytokines levels characterized by IL-12p70, IL-10, IL-4, and IFN-?. Interestingly, we observed that rSIP stimulate Toll Like Receptor (TLR)2 and TLR4, individually expressed by Human embryonic kidney (HEK) 293-derived TLR reporter cells. These findings suggest that rSIP is a new potential protein TLR agonist adjuvant and may be employed in the development of new vaccines. |
| Idioma: | eng |
| Base de Datos: | PubMed |
| Ver Más: | https://doi.org/10.3390/vaccines8010029 |